 |
 |
 |
 |
 |
Treatment Name: |
 |
Talampanel, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
 |
 |
 |
 |
Phase: |
 |
Phase 2 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1483 NCT00082992 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Not Allowed Prior Chemotherapy is Not Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
04/29/2007 |
 |
 |
 |
 |
Tumor Types: |
 |
Glioblastoma Multiforme |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
Induction therapy: Patients undergo radiotherapy once daily on days 1-5. Beginning on day 1 of radiotherapy, patients receive oral talampanel 3 times daily on days 1-7. Treatment repeats weekly for 6 weeks.
Maintenance therapy: Beginning immediately after the completion of induction therapy, patients receive oral talampanel 3 times daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy Radiation |
 |
 |
 |
 |
Contact: |
 |
James Markert M.D. Associate Professor of Neurosurgery University of Alabama at Birmingham Comprehensive Cancer Center Comprehensive Cancer Center Birmingham, AL 35294 USA Phone: 205-975-3251 Fax: 205-975-3203 E-mail: kpowell@uabmc.edu Website: |
 |
 |